CSPG4 and benign neoplasm: Considering our novel finding that the inhibition of CK2 reduces NG2 expression and NG2-dependent cell migration in JA, SGC-CK2-1 may, thus, be a promising candidate for the future treatment of this benign tumor type, which is found particularly in young patients.